Novazyme Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novazyme Pharmaceuticals Inc.
In his first address to a joint session of Congress, Trump spoke of a need to "slash the restraints" at US FDA and other regulatory agencies, and he reminded legislators about his executive order to eliminate two regulations for each new one written. The president's anti-regulatory posture comes as the White House is expected to seek budget cuts for domestic agencies.
US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.
In Vivo presents another installment of our quarterly review of dealmaking--in this case July 2001-September 2001. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
- Other Names / Subsidiaries
- Genzyme Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.